No CrossRef data available.
Article contents
1051 – Lurasidone In The Treatment Of Early-stage Schizophrenia: a Post-hoc Analysis Of Three Pooled Acute Treatment Studies
Published online by Cambridge University Press: 15 April 2020
Abstract
Lurasidone has demonstrated efficacy treating adults with schizophrenia, the majority of them with chronic, multi-episode schizophrenia.
To assess baseline characteristics and evaluate efficacy of lurasidone in patients with early-stage schizophrenia (ESS).
Evaluate efficacy of lurasidone in patients with ESS.
A pooled analysis of patients with ESS (defined as onset of illness within 3 years of study entry) from three, 6-week, randomized, placebo-controlled, phase 3 trials was performed. Additional analysis was conducted for patients with onset within 5 years. Efficacy was evaluated using a mixed-model repeated-measures analysis of change in PANSS total score and CGISeverity score. Treatment response was defined as ≥20% improvement in PANSS total score from baseline.
857 subjects were randomized to lurasidone and 366 to placebo of which 102(11.9%) lurasidone and 44(12.0%) placebo subjects had ESS (onset within 3 years). Among 146 ESS subjects, 70.5% were male, mean age was 28.6 years. Baseline PANSS total and CGI-S scores were 96.8 and 5.0 respectively. Lurasidone treatment of early-stage schizophrenia subjects showed significant improvement vs placebo in PANSS total score (-25.9 vs -17.3; p< 0.05, effect size=0.42), PANSS positive (-9.6 vs 6.0; p< 0.01) and negative (-5.6 vs -3.2; p=0.014) subscale scores, and improvement in CGI-S score (-1.7 vs -1.3; p=0.089, effect size=0.36). Responder rates were 69% for lurasidone vs 48% for placebo (NNT=5). Similar results were observed in subjects with within 5 years of onset of illness.
In this subgroup analysis, lurasidone was effective in the treatment of patients with early-stage schizophrenia.
- Type
- Abstract
- Information
- European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E459
- Copyright
- Copyright © European Psychiatric Association 2013
Comments
No Comments have been published for this article.